Q1 EPS Forecast for Rhythm Pharmaceuticals Raised by Analyst

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) - HC Wainwright upped their Q1 2025 earnings per share estimates for shares of Rhythm Pharmaceuticals in a research note issued to investors on Monday, March 3rd. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.68) per share for the quarter, up from their prior estimate of ($0.81). HC Wainwright has a "Buy" rating and a $70.00 price target on the stock. The consensus estimate for Rhythm Pharmaceuticals' current full-year earnings is ($4.32) per share. HC Wainwright also issued estimates for Rhythm Pharmaceuticals' Q2 2025 earnings at ($0.70) EPS, Q3 2025 earnings at ($0.68) EPS, Q4 2025 earnings at ($0.72) EPS and FY2025 earnings at ($2.79) EPS.

A number of other research firms have also recently commented on RYTM. Canaccord Genuity Group boosted their target price on shares of Rhythm Pharmaceuticals from $80.00 to $81.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. Morgan Stanley reiterated an "overweight" rating and set a $72.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Friday. Stifel Nicolaus initiated coverage on Rhythm Pharmaceuticals in a report on Wednesday, March 5th. They set a "buy" rating and a $78.00 target price for the company. The Goldman Sachs Group lifted their price target on Rhythm Pharmaceuticals from $59.00 to $66.00 and gave the stock a "buy" rating in a research note on Thursday, December 5th. Finally, JMP Securities reissued a "market outperform" rating and issued a $75.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $69.31.

Remove Ads

Rhythm Pharmaceuticals Price Performance

NASDAQ RYTM traded down $2.23 on Thursday, hitting $48.56. The company had a trading volume of 428,678 shares, compared to its average volume of 491,576. The company has a market capitalization of $3.07 billion, a PE ratio of -11.21 and a beta of 2.30. Rhythm Pharmaceuticals has a 12-month low of $35.17 and a 12-month high of $68.58. The company's fifty day moving average price is $56.53 and its 200-day moving average price is $54.61.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.03). Rhythm Pharmaceuticals had a negative return on equity of 367.36% and a negative net margin of 230.07%. The business had revenue of $41.83 million for the quarter, compared to analyst estimates of $38.48 million.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Rhythm Pharmaceuticals in the 4th quarter valued at $4,259,000. GF Fund Management CO. LTD. purchased a new stake in Rhythm Pharmaceuticals in the 4th quarter valued at about $72,000. Voloridge Investment Management LLC lifted its position in Rhythm Pharmaceuticals by 7.7% in the fourth quarter. Voloridge Investment Management LLC now owns 380,537 shares of the company's stock valued at $21,302,000 after buying an additional 27,214 shares during the last quarter. Two Sigma Advisers LP boosted its stake in Rhythm Pharmaceuticals by 2.3% during the fourth quarter. Two Sigma Advisers LP now owns 13,100 shares of the company's stock worth $733,000 after buying an additional 300 shares during the period. Finally, State of Wyoming purchased a new position in Rhythm Pharmaceuticals during the fourth quarter worth about $61,000.

Insider Transactions at Rhythm Pharmaceuticals

In other news, insider Joseph Shulman sold 1,281 shares of the stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $59.43, for a total value of $76,129.83. Following the completion of the sale, the insider now owns 2,657 shares of the company's stock, valued at $157,905.51. This represents a 32.53 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Hunter C. Smith sold 2,215 shares of the firm's stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $57.22, for a total transaction of $126,742.30. Following the sale, the chief financial officer now owns 109,929 shares of the company's stock, valued at $6,290,137.38. This represents a 1.98 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 32,787 shares of company stock worth $1,901,443 in the last quarter. Company insiders own 5.60% of the company's stock.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.